This is a retrospective evaluation of the impact of a double dose regimen of immunotherapy use in cancer treatment compared to the single-dose regimen on the occurrence of clinically significant adverse events. The aim of this study is to provide evidence-based arguments to help clinicians to propose the best treatment regimen for each patient.
Study Type
OBSERVATIONAL
Enrollment
500
Uhmontpellier
Montpellier, France
To compare the incidence of clinical significant toxicities
To compare the incidence of clinical significant toxicities reported for patients treated with a cancer immunotherapy on a simple dose regiment versus double dose regimen
Time frame: 18 months
To describe the incidence
To describe the incidence, type and severity of overall toxicities (serious and non-serious) reported with single and double dose cancer immunotherapy regimens
Time frame: 18 months
To identify risk factors for the development of severe toxicity
To identify risk factors for the development of severe toxicity
Time frame: 18 months
To describe the management and evolution of toxicities
To describe the management and evolution of toxicities
Time frame: 18 months
To describe the clinical oncologic response
To describe the clinical oncologic response
Time frame: 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.